Investment PotentialDespite a slight reduction in price target, the stock is still seen as offering a favorable reward opportunity for high investment risk.

Product DevelopmentThe company expects to submit its MyoVista device for FDA approval, which could lead to significant advancements in their product offerings.

Revenue OpportunitiesCMS reimbursement for AI-ECG technology paves the way for monetization, creating potential revenue opportunities for HeartSciences.

Bears Say

Cash FlowThe company held $2.6M in cash and $2.5M in debt and will need to access its equity line or other sources of capital.

EarningsThe company's earnings per share came in lower than the consensus estimate, indicating higher expenses than anticipated.

Financial StabilityThe company will need to raise substantial cash to maintain its operations until it reaches its expected monetization phase.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.71% Insiders

0.89% Mutual Funds

1.75% Other Institutional Investors

96.48% Public Companies and Individual Investors

Detailed Ownership Overview >

HSCS FAQ

What was Heart Test Laboratories, Inc.’s price range in the past 12 months?

Heart Test Laboratories, Inc. lowest stock price was $2.36 and its highest was $5.30 in the past 12 months.

What is Heart Test Laboratories, Inc.’s market cap?

Heart Test Laboratories, Inc.’s market cap is $4.22M.

When is Heart Test Laboratories, Inc.’s upcoming earnings report date?

Heart Test Laboratories, Inc.’s upcoming earnings report date is Sep 11, 2025 which is in 70 days.

How were Heart Test Laboratories, Inc.’s earnings last quarter?

Heart Test Laboratories, Inc. released its earnings results on Mar 13, 2025. The company reported -$2.545 earnings per share for the quarter, missing the consensus estimate of -$2.305 by -$0.24.

Is Heart Test Laboratories, Inc. overvalued?

According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Heart Test Laboratories, Inc. pay dividends?

Heart Test Laboratories, Inc. does not currently pay dividends.

What is Heart Test Laboratories, Inc.’s EPS estimate?

Heart Test Laboratories, Inc.’s EPS estimate is -2.31.

How many shares outstanding does Heart Test Laboratories, Inc. have?

Heart Test Laboratories, Inc. has 1,080,946 shares outstanding.

What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?

Heart Test Laboratories, Inc. reported an EPS of -$2.545 in its last earnings report, missing expectations of -$2.305. Following the earnings report the stock price went up 2.703%.

Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?

Currently, no hedge funds are holding shares in HSCS

Company Description

Heart Test Laboratories, Inc.

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.